Page 25 - Biyolojik Ajan Kullanan Romatolojik Hastalarda Enfeksiyon Yönetimi

Biyolojik Ajan Kullanan Romatolojik Hastalarda Enfeksiyon Yönetimi

KaynaKlar 9. Chiricozzi A, Saraceno R, Cannizzaro MV, Niscito SP, Chimenti S, Giun-
ta A. Complete resolution of erythrodermic psoriasis in an HIV and
1. Fink DL, Hedley L, Miller RF. Systematic review of the efficacy and sa- HCV patient unresponsive to antipsoriatic treatments after highly
fety of biological therapy for inflammatory conditions in HIV-infected active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Te-
individuals. International Journal of STD & AIDS 2016(0):1-10. nofovir). Dermatol Basel Switz 2012;225:333-7.
2. Castillo JJ, Echenique IA. Rituximab in combination with chemothe- 10. Kaur PP, Chan VC, Berney SN. Successful etanercept use in an HIV-po-
rapy versus chemotherapy alone in HIV associated non-Hodgkin ly- sitive patient with rheumatoid arthritis. J Clin Rheumatol Pract Rep
mphoma: a pooled analysis of 15 prospective studies. Am J Hematol Rheum Musculoskelet Dis 2007;13:79–80.
2012;87:330-3.
11. Cepeda EJ, Williams FM, Ishimori ML, Weishman MH, Reveille JD. The
3. Siva C, Brasington RD. Worsening of arthritis with antiretroviral the- use of anti-tumour necrosis factor therapy in HIV-positive individuals
rapy: the coexistence of rheumatoid arthritis and human immunode- with rheumatic disease. Ann Rheum Dis 2008;67:710-2.
ficiency virus infection revisited. J Clin Rheumatol Pract Rep Rheum
Musculoskelet Dis 2001;7:42-6. 12. The British Society for Rheumatology biologic DMARD safety guideli-
nes in inflammatory arthritis. Holroyd CR, Seth R, Bukhari M, Malaviya
4. Calabrese LH, Kirchner E, Shrestha R. Rheumatic complications of A, Holmes A, Curtis E, et al for the British Society for Rheumatology
human immunodeficiency virus infection in the era of highly acti- Standards, Guidelines and Audit Working Group. Rheumatology
ve antiretroviral therapy: emergence of a new syndrome of immu- 2019;58:e3-e42.
ne reconstitution and changing patterns of disease. Semin Arthritis
Rheum 2005;35:166-74. 13. National Institute for Health and Care Excellence (NICE). HIV testing:
increasing uptake among people who may have undiagnosed HIV.
5. Yang X, Miyawaki T, Kanegane H. Lymphoproliferative disorders in NICE Guideline 60. London: NICE, 2016. https://www.nice.org.uk/gu-
immunocompromised individuals and therapeutic antibodies for idance/ng60 (May 2018).
treatment. Immunotherapy 2013;5:415-25.
14. Toruner M, Loftus EV, Harmsen WS Zinsmeister AR, Orenstein R, Sand-
6. Yao Q, Frank M, Glynn M. Rheumatic manifestations in HIV-1 infected born WJ, et al. Risk factors for opportunistic infections in patients with
in-patients and literature review. Clin Exp Rheumatol 2008;26:799- inflammatory bowel disease. Gastroenterology 2008;134:929-36.
806.
15. Curtis JR, Yang S, Patkar NM, Chen L, Singh JA, Cannon GW, et al. Risk
7. Fox C, Walker-Bone K. Evolving spectrum of HIVassociated rheumatic of hospitalized bacterial infections associated with biologic treat-
syndromes. Best Pract Res Clin Rheumatol 2015;29:244-58. ment among US veterans with rheumatoid arthritis. Arthritis Care
8. Sellam J, Bouvard B, Masson C, Rousiere M, Villoutreix C, Lacombe K, Res 2014;66:990-7.
et al. Use of infliximab to treat psoriatic arthritis in HIV-positive pa-
tients. Jt Bone Spine Rev Rhum 2007;74:197–200.

15